Does TL1A-DR3 signaling play a role in your research?

news August 12 2019

InVivoMAb anti-mouse TL1A (TNFSF15)

The 5G4.6 monoclonal antibody reacts with the TNF family member TL1A, also known as TNFSF15. TL1A is expressed on activated T cells, dendritic cells, monocytes and endothelial cells. TL1A expression has been shown to be induced by pro-inflammatory stimuli such as TNFα and IL-1α. In contrast to the TNFα receptors, which are expressed on essentially all cells, the receptor for TL1A, DR3 (TNFRSF25), is primarily expressed on T cells, NK cells, and NKT cells, thereby limiting the effects of TL1A. TL1A-DR3 interactions are thought to promote effector T cell proliferation at the site of inflammation and in draining lymph nodes. Blockade of TL1A-DR3 interactions strikingly reduces pathology in several animal models in which autoreactive T cells play a role. TL1A has been linked to inflammatory bowel disease. The 5G4.2 antibody has been shown to block TL1A binding to DR3 and reduce disease severity in mouse models of colitis.

This Antibody Is Useful For:

  • in vivo TL1A neutralization
  • Flow cytometry

As always Bio X Cell antibodies are specifically formulated for in vivo use and feature:

  • 95% purity
  • Ultra-low endotoxin levels
  • Preservative, stabilizer, and carrier protein-free